Neumora Therapeutics is trading 6.67% up now at $0.80, with no fresh company-specific announcement or earnings release clearly explaining the pre-market rebound.
- It closed September 17, 2026, at $0.75.
- Recent NMRA-215 toxicology coverage reflects previously reported data, rather than a new catalyst.
- The broader risk-on backdrop may be supporting the move, with the Nasdaq Composite up 0.60% and S&P 500 up 0.37%.